ABSTRACT Background Serum neurofilament‐light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient‐ and disease‐level determinants of sNfL and sGFAP and to evaluate their ability to support differential diagnosis in neuromyel...
M. Rival, F. Rollot, Sabine Laurent-Chabalier et al.· European Journal of Neurolog...· 0 citations
Importance
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating disease distinct from multiple sclerosis (MS) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Magnetic resonance imaging (MRI) is central to confirming attacks, defining lesion di...
E. Flanagan, Brenda L. Banwell, Laura Cacciaguerra et al.· JAMA Neurology· 0 citations
Treatment de-escalation is sometimes necessary because of adverse effects, comorbidities, infections, treatment fatigue, or life circumstances such as pregnancy, but in pregnancy, management requires balancing maternal disease control with fetal safety, with strategies ranging from continuation of selected therapies to...
Y. Hacohen, G. Androdias, G. Arrambide et al.· Neurology· 0 citations
Management of attacks as well as the prevention of relapses is crucial to limit functional sequelae and disability, and the rapid and individualized management of attacks is crucial to limit functional sequelae and disability.
L. Giorgi, R. Marignier, J. Pique et al.· Revue neurologique (Paris)· 0 citations
A review of current evidence on established and emerging fluid biomarkers in NMOSD and MOGAD, with emphasis on analytical performance, biological relevance, and clinical utility, and outlines priorities for future research.
S. Mariotto, Á. Cobo-Calvo, M. Khalil et al.· Neurology(R) neuroimmunology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
